Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 15;11:623313. doi: 10.3389/fonc.2021.623313

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Liu, Gao, Xie, Li, Zhai and Xu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The correlations of different risk group with copy number alterations, tumor mutation burden, neo-antigens, tumor stemness, clonal status and immune-/chemotherapy response. (A) Arm-level copy number amplification and deletion. (B) Focal-level copy number amplification and deletion; (C) Tumor mutant burden difference. (D) Neo-antigens. (E) Tumor stemness difference represented by the mRNAsi. (F) Clonal status. (G, H) Immunotherapy response based on TIDE website and estimated IC50 indicates the efficiency of chemotherapy in TCGA. (I, J) Immunotherapy response and estimated IC50 in MSKCC dataset. All the survival analysis are based on the recurrence free survival data.